108(2):187 -195. Heat Biologics, Inc. Investigational Product: Vesigenurtacel -L Protocol HS410 -101 CONFIDENTIAL Version 8.0; 03 Feb 2016 Page 86 of 86 16 Huang CJ, Hamilton AS, Lo M, et al. (2008) Predictors of intravesical therapy for nonmuscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2002 patterns of care project. J. Urol . 180(2): 520 -524. 17 Chamie K, S aigal S, Lai J et al. (2011) Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 117(4):5392 -5401. 18 Vatsan RS, Bross PF, Liu K, et al. (2013) Regulation of immuno therapeutic products for cancer and FDA’s role in product development and clinical evaluation. J. Immunother. Cancer 1:5. 19 Kantoff PW, Higano CS, Shore ND, et al. (2010) Sipuleucel -T immunotherapy for castration resistant prostate cancer. NEJM 363:411 -422. 20 Robert C, Thomas L, Bondarenko I, et al. (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. NEJM 364:2517 -2526. 21 Wood C, Srivastava P, Bukowski R, et al. (2008) An adjuvant autologous therapeutic vaccine (HSPPC -96, vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicenter, open -label, randomized phase III trial. Lancet 372:145 -154.